Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447502 | 1.00 | CTSK (0.54) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL7300364 | 0.88 | CTSK (0.49) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL1861195 | 0.87 | CTSK (0.55) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL8365044 | 0.87 | CTSK (0.55) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL1861194 | 0.87 | CTSK (0.55) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL7264559 | 0.85 | CTSK (0.53) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL7264560 | 0.85 | CTSK (0.53) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL9104062 | 0.84 | CTSK (0.55) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL9104071 | 0.84 | CTSK (0.55) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL13305814 | 0.83 | CTSK (0.55) | CTSKCTSSCTSLCTSBAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0311012-B1 | Glaucoma treatment | ABBOTT LAB (US) | 1995-03-29 | — | — | EP | disclosed |
| US-5346887-A | Mixture of tripeptide renin inhibitor and steroid antiinflammatory agent | ABBOTT LABORATORIES (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0229667-B1 | Peptidylaminodiols | ABBOTT LAB (US) | 1994-07-13 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0255082-B1 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AG (DE) | 1993-12-01 | — | — | EP | disclosed |
| US-5214129-A | Amidation of a protected amino acid by an di-O-protected dihydroxy-containing amine and coupling with a carboxylic acid; deprotecting; renin inhibitors; hypotensive agents | ABBOTT LABORATORIES (US) | 1993-05-25 | — | — | US | disclosed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
| US-4845079-A | HYPOTENSIVE, RENIN INHIBITION | ABBOTT LABORATORIES | 1989-07-04 | — | — | US | disclosed |
| EP-0311012-A2 | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0310015-A2 | Renin-inhibiting dipeptides, process for their preparation, medicines containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | disclosed |
| EP-0295294-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-12-21 | — | — | EP | disclosed |
| WO-1988005050-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-07-14 | — | — | WO | disclosed |
| US-4725583-A | ANTIHYPERTENSIVE | ABBOTT LABORATORIES (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0255082-A2 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
| EP-0189203-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CTSK 92/4885CTSS 82/4885CTSL 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.